In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following: Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05 Presenters: Erika Hamilton, MD, FASCO Chief Development Officer, Late Phase Director, Breast Cancer Research Program Sarah Cannon Research Institute (SCRI) Nashville, Tennessee Ian Krop, MD, PhD Professor of Medicine, Yale School of Medicine Associate Cancer Center Director for Clinical Research Yale Cancer Center New Haven, Connecticut Content based on an online CME program supported by an educational grant from Pfizer. Link to full program: https://bit.ly/4esvN9x Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related